An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback